The invention provides cationic liposome encapsulated antimonial drugs formulations. The drug-loaded liposome have enhanced efficacy as antileismanial agents and provide improved therapeutic index as compared to the free drug.

This invention seems to be therapeutically effective against SAG-resistant parasite thereby focusing its importance during outbreak of resistant strain.

The liposomal drug can be administered to infected model by intravenous route. However, when the drug need to be assisted against cutaneous leishmaniasis the formulations must be injected either intralesionally or intramuscular